CARB-X teams up with HelixBind to support the development of a test to diagnose life-threatening bloodstream infections linked to sepsis
Summary
All the projects in the Powered by CARB-X are in the early stages of development, but if successful, they offer great potential in the fight against life-threatening drug-resistant bacteria.” “We believe RaPID will enable clinicians to place patients on targeted antimicrobial days sooner, leading to better outcomes, reduced time in the hospital, and improved antibiotic stewardship,” said Alon Singer, PhD, Founder and CEO of HelixBind. Its proprietary RaPID platform provides culture-free characterization of bacterial and fungal pathogens and their resistance mechanisms direct from patient specimens, enabling clinicians to quickly diagnosis and monitor infection progression to ensure prompt and appropriate care. 2711000 (whose registered office is at 215 Euston Road, London NW1 2BE, UK) HHS is the principal federal agency for protecting the health of all Americans and providing essential human services, especially for those who are least able to help themselves. Within ASPR, BARDA provides a comprehensive integrated portfolio approach to the advanced research and development, innovation, acquisition, and manufacturing of vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products for public health emergency threats. By maintaining its focus on entrepreneurship, education and career development programs, CLSI supports the foundations of innovation that have made California home to the world’s most prominent life sciences ecosystem.